MarketBeat
27 Sept 2026, 12:02 UTC · 2h ago
Verdict
Headline takes no side. We score KMDA +0.80 across five claims — strongly bullish.
+0.80strongly bullish
More positive than 88% of ticker scores this week
What the story claims
5 claims · scored −1 bearish … +1 bullish · 1 new · 4 priced in
Kamada expects 2026 revenue of $200 million to $205 million and EBITDA of $50 million to $53 million.
Priced inanalysis of company presentation
So whatWith $100M revenue already booked in H1, the company needs only ~100% growth in H2 to hit the midpoint.
More positive than 93% of claims this week
The board adopted a policy to pay at least 50% of net profit as dividends.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 3 movers · tap to explore
Priced inanalysis of company presentation
More positive than 79% of claims this week
A three-year, $50 million plasma supply agreement will begin contributing roughly $17 million annually before year-end.
Priced inannounced in July
So whatThis high-margin revenue stream provides a baseline for 2027 growth beyond the current Kedrab-heavy outlook.
More positive than 66% of claims this week
The company expects two additional biosimilar launches this quarter and another two to three next year.
Newannounced in company presentation
So whatThese launches contribute to the $15M-$20M incremental sales target forecast over the next four to five years.
More positive than 53% of claims this week
Data for the SHIELD study evaluating CYTOGAM in kidney-transplant recipients are expected in late 2028.
Priced inanalysis of company presentation
So whatThe long horizon means this catalyst will not impact the valuation multiple for several years.
More positive than 45% of claims this week
Which stocks this story touches
More positive than 88% of ticker scores this week
The company reported strong revenue and EBITDA growth, positive first-half results, a clear growth strategy, and increased demand for its lead product Kedrab.
Near neutral — 92% of ticker scores this week are stronger
Takeda is mentioned only as a marketing partner that pays royalties to Kamada, with no material news affecting Takeda's own valuation.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Seeking Alpha
1h ago
—
KMDA hasn't traded since this ran. Last close $8.72 (Sep 25); the reaction starts at the next open.
KMDA chart →
